Submitted on September 18, 2017 - USP Comment Letter to FDA in conjunction with the July 18, 2017 meeting on “Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access” with regards to facilitating increased competition in the market for prescription drugs through the approval of generic medicines.
Docket No. FDA-2017-N-3615, Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access; Public Meeting; Request for Comments
Public Policy